Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men: age over ≥ 18 years or women: age over ≥ 18 years with finished reproductivity according to the following definition:~* ≥ 12 month persistent natural (spontaneous) amenorrhoea (women aged \<50: additionally: FSH \>40MIE/ml and estrogen deficiency of \<30pg/ml or a negative estrogen test)~* status post hysterectomy and / or bilateral oophorectomy~* finished reproduction planning~* secure diagnosis of bone marrow edema using MRT~* current osteologic basic laboratory values (≤ 4 weeks before V2) according to DVO criteria~* presence of an personally signed informed consent for the participation in the study~Exclusion Criteria:~* - subchondral bone loss or already occurred cartilage damage due to the bone marrow edema~* reactive bone marrow edema with advanced arthrotic changes in the adjacent joint (grade III and IV according to Kellgren and Lawrence)~* patients with edematous changes in bone marrow due to the diagnosis of M. Sudeck / algodystrophy / Complex Regional Pain Syndrome (CRPS)~* patients with known hypo- and hyperparathyroidism, osteogenesis imperfecta, osteomalacia, M. Paget or another systemic skeletal diseases, except osteoporosis~* patients with bone necrosis in the painful skeletal region~* patients with infectious process at the affected bone or the adjacent joint and adjacent soft parts, respectively~* patients with diagnosed or assumed rheumatoid arthritis, Lupus erythematodes, collagenosis or vasculitides~* patients with advanced renal insufficiency (GFR according to Cockcroft~  / Gault ≤ 40 ml/min/KO)~* patients with malignant diseases with osseous manifestation in anamnesis/history~* status post malignant basic/primary disease with large dosed chemotherapy~* current or massive dose therapy completed before less than 6 weeks (\>7.5mg prednisolon equivalent) with glucocorticoids~* patients with a malignant tumor disease within the past 5 years, independent from the affected organ system and independent from the implemented treatment, the presence of a relapse or metastatic invasion, except basal cell carcinoma and squamous-cell carcinoma of the skin Current treatment due to uveitis~* vague/ambiguous hyper- or hypocalcemia, hyper- or hypophosphatemia~* etiological vague/ambiguous AP-increase~* symptomatic renal calculus or nephrocalcinosis within 2 years before V2~* recent fracture within the last 3 months independent of the localisation~* non consolidated fractures~* previous treatment with i.v. bisphosphonates within the last 12 months~* previous treatment with oral bisphosphonates within the last 12 months and longer than 3 months~* pre-treatment with prostacyclin analogs (Ilomedin® / Iloprost®) within the past 6 months~* Current treatment due to inflammatory diseases of the jaw area as well as planned tooth extractions or tooth extractions less than 6 months ago or oral surgery implant treatment~* pregnancy or nursing period~* patients immediately involved in the conduction of the trial and relatives~* patients with current proceedings related to the bone marrow edema~* patients for which the participation in the study carries an increased risk under consideration of the health condition due to the assessment of the investigator~* participation in another clinical trial within 30 days before study start or during the trial~* participation of patient who might be dependent on the investigator, also the spouse, parents or children

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclasta (Type: ACTIVE_COMPARATOR): None
- NaCl Solution (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).